Yes - Safety Profile in all tests to date has been very positive.
Results of Phase 2 of the Rett trials...
http://www.neurenpharma.com/irm/PDF...ificantclinicalbenefitinpediatricRettsyndrome
Phase 3 is next.
Management said they would meet with FDA to approve Phase 3 - Done and positive outcome
Management said they would consolidate shares to appeal more to USA institutional investors - Done and positive outcome
Management have been saying that they are talking to potential partners to take the product(s) to the next level and fast track to production - Next Year!
evidence, page-2
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |